Scholars Central

Conference abstractPublished 15 Apr 2013

Treatment modalities in skin-limited primary cutaneous T-cell lymphomas

Authors: Matthias Karrasch

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma. In skin-limited disease, MF varies from patches, plaques and infiltrated tumours. In such case, treatment modalities targeting the skin are very helpful. Phototherapy is widely used for such purposes. However, there is an urgent need for multicenter trials involving defined patient populations using rigorous assessment criteria. Psoralen plus ultraviolet A (PUVA) is the standard treatment for early and skin-limited stages of MF. There have been no adequate randomized controlled trials with sufficient power comparing this modality with other therapies. A phase III randomized clinical study (EORTC 21011, NCT 00056056) has been conducted in order to assess disease response and to compare combined bexarotene (TargretinÃ?¯Ã?¿Ã?½) and PUVA vs. PUVA alone in patients with stage IB and IIA MF. The primary endpoint of this study was the overall response rate [complete clinical response (CCR) plus partial response (PR)]. The median duration of response was 9.7 months for PUVA vs. 5.8 months for the combination arm (P=0.33). CCR was seen in 25 patients of whom 10 received PUVA alone (CCR 22%) and 15 received combination therapy (CCR 31%) (P=0.45). There was a trend towards fewer PUVA sessions needed to achieve CCR in the combination arm (median 22) compared with the PUVA arm (median 27.5) (P=0.11). Similarly, a trend towards lower UVA dose required to achieve CCR in the combination arm (median 55.8 J cm -2 ) compared with the PUVA arm alone (median 117.5 J cm -2 ) (P=0.5) was observed. No significant difference in response rate or response duration was observed in this study. However, there was a trend towards fewer PUVA sessions and lower UVA dose required to achieve CCR in the combination arm (PUVA + bexarotene).

Subjects

Dermatology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Dermatology Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Dermatology Research
  • SubjectDermatology
  • BylineArticles whose byline prints “Matthias Karrasch”